Latest news with #EOM
Associated Press
01-06-2025
- Business
- Associated Press
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 1, 2025-- To address the rising costs of cancer drugs, investigators from The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, explored the impact of engaging a remote clinical pharmacist in reducing the total cost of care (TCOC) within the Enhancing Oncology Model (EOM) from the Centers for Medicare and Medicaid Services (CMS). From July 1, 2023, to December 31, 2024, seven ClinReview pharmacists (CRPs) within five EOM-participating practices in The Network evaluated more than 5,600 patients for medication initiatives. During the same period, The Network had 12 practices in the EOM nationwide, accounting for approximately 50% of all providers participating in the program. A total of 1,271 interventions were identified, with 1,180 accepted. The sum of TCOC reduction amounted to $8,982,235. Six medication initiatives were implemented and the breakdown of each initiative and average TCOC reduction per intervention are shown in the table below and will be presented in a rapid oral presentation at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting: In addition to the six medication initiatives outlined above, the CRPs contributed an additional $1,201,326 in medication savings associated with drug selection. 'With the national cost of cancer care estimated to exceed $245 billion by 2030, this study provides a clear roadmap for oncology practices looking to reduce costs and improve patient outcomes,' said lead author Daniel Kendzierski, PharmD, senior clinical pharmacist, The Network. 'These findings underscore the critical role of pharmacist-driven medication interventions in driving the success of value-based care models in oncology.' Study Methodology Medication initiatives were clinically evaluated and adopted at an individual practice level and included moAB dose rounding, pembrolizumab dose banding, biosimilar TIC to preferred products, use of a preferred PD-1 agent in metastatic NSCLC, decreased upfront usage of long-acting GF in metastatic cancer, and preferred use of zoledronic acid over alternatives. CRPs remotely reviewed oncology treatment orders for cost-savings opportunities, updated eligible treatments per practice protocols, or reviewed with the treating oncologist. Interventions were submitted by the CRPs into a tracking system and marked as an EOM-related intervention. TCOC reduction was calculated using the difference between the CMS allowable for the original treatment ordered and the new order. Other Research at ASCO 2025 Physicians in The Network are affiliated with dozens of studies being presented at ASCO 2025. Their research highlights clinical and operational findings covering key topics such as the impact of AI on care delivery, access to oncology resources for minority patient populations, and patient experiences with novel therapies. 'As cancer care costs continue to escalate, community oncology practices need novel therapies and innovative solutions to deliver high-quality, affordable care,' said Leslie Busby, MD, Pharmacy & Therapeutics Committee chair and incoming chief medical officer, The Network. 'Research presented at this year's ASCO around digital transformation and patient care delivery in community settings highlights the direct impact practices in The Network have on the communities they serve. This research helps inform how we can continue driving value-based care forward and improving cancer care for all oncology patients.' The Network is supported by McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. Click here for a full list of SCRI-affiliated studies and presentations and here for Ontada-affiliated abstracts. Expert Panel on Precision Medicine in Community Oncology during ASCO 2025 Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 4, 2025, at 12:10pm ET, titled, 'The Future is Now: Digital Transformation Unleashes Precision Medicine in Community Oncology.' Click here to register and join the panelists as they share their insights and perspectives on actionable steps and solutions for community oncology practices to seamlessly integrate precision medicine into their care offerings: ### About The US Oncology Network Every day, The US Oncology Network (The Network) helps more than 2,700 independent providers deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere. About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. View source version on CONTACT: Media Contact The US Oncology Network Claire Crye, Communications [email protected] Health on behalf of The US Oncology Network Christine Murphy, Media Relations [email protected] KEYWORD: TEXAS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL PRACTICE MANAGEMENT MANAGED CARE ONCOLOGY SOURCE: The US Oncology Network Copyright Business Wire 2025. PUB: 06/01/2025 08:00 AM/DISC: 06/01/2025 08:01 AM
Business Wire
01-06-2025
- Health
- Business Wire
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
THE WOODLANDS, Texas--(BUSINESS WIRE)--To address the rising costs of cancer drugs, investigators from The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, explored the impact of engaging a remote clinical pharmacist in reducing the total cost of care (TCOC) within the Enhancing Oncology Model (EOM) from the Centers for Medicare and Medicaid Services (CMS). From July 1, 2023, to December 31, 2024, seven ClinReview pharmacists (CRPs) within five EOM-participating practices in The Network evaluated more than 5,600 patients for medication initiatives. During the same period, The Network had 12 practices in the EOM nationwide, accounting for approximately 50% of all providers participating in the program. A total of 1,271 interventions were identified, with 1,180 accepted. The sum of TCOC reduction amounted to $8,982,235. Six medication initiatives were implemented and the breakdown of each initiative and average TCOC reduction per intervention are shown in the table below and will be presented in a rapid oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: In addition to the six medication initiatives outlined above, the CRPs contributed an additional $1,201,326 in medication savings associated with drug selection. 'With the national cost of cancer care estimated to exceed $245 billion by 2030, this study provides a clear roadmap for oncology practices looking to reduce costs and improve patient outcomes,' said lead author Daniel Kendzierski, PharmD, senior clinical pharmacist, The Network. 'These findings underscore the critical role of pharmacist-driven medication interventions in driving the success of value-based care models in oncology.' Study Methodology Medication initiatives were clinically evaluated and adopted at an individual practice level and included moAB dose rounding, pembrolizumab dose banding, biosimilar TIC to preferred products, use of a preferred PD-1 agent in metastatic NSCLC, decreased upfront usage of long-acting GF in metastatic cancer, and preferred use of zoledronic acid over alternatives. CRPs remotely reviewed oncology treatment orders for cost-savings opportunities, updated eligible treatments per practice protocols, or reviewed with the treating oncologist. Interventions were submitted by the CRPs into a tracking system and marked as an EOM-related intervention. TCOC reduction was calculated using the difference between the CMS allowable for the original treatment ordered and the new order. Other Research at ASCO 2025 Physicians in The Network are affiliated with dozens of studies being presented at ASCO 2025. Their research highlights clinical and operational findings covering key topics such as the impact of AI on care delivery, access to oncology resources for minority patient populations, and patient experiences with novel therapies. 'As cancer care costs continue to escalate, community oncology practices need novel therapies and innovative solutions to deliver high-quality, affordable care,' said Leslie Busby, MD, Pharmacy & Therapeutics Committee chair and incoming chief medical officer, The Network. 'Research presented at this year's ASCO around digital transformation and patient care delivery in community settings highlights the direct impact practices in The Network have on the communities they serve. This research helps inform how we can continue driving value-based care forward and improving cancer care for all oncology patients.' The Network is supported by McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. Click here for a full list of SCRI-affiliated studies and presentations and here for Ontada-affiliated abstracts. Expert Panel on Precision Medicine in Community Oncology during ASCO 2025 Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 4, 2025, at 12:10pm ET, titled, 'The Future is Now: Digital Transformation Unleashes Precision Medicine in Community Oncology.' Click here to register and join the panelists as they share their insights and perspectives on actionable steps and solutions for community oncology practices to seamlessly integrate precision medicine into their care offerings: Jason Hammonds, chief operating officer, Oncology & Specialty, McKesson Andrew McKenzie, PhD, vice president, Personalized Medicine, SCRI and scientific director of Genospace Eric Lander, MD, oncologist, Minnesota Oncology, a practice in The US Oncology Network Terri Conneran, founder of KRAS Kickers ### About The US Oncology Network Every day, The US Oncology Network (The Network) helps more than 2,700 independent providers deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere. About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada ®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.
Yahoo
01-06-2025
- Business
- Yahoo
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
Findings show engagement of remote clinical pharmacists reduced total cost of cancer care by nearly $9 million across five practices THE WOODLANDS, Texas, June 01, 2025--(BUSINESS WIRE)--To address the rising costs of cancer drugs, investigators from The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, explored the impact of engaging a remote clinical pharmacist in reducing the total cost of care (TCOC) within the Enhancing Oncology Model (EOM) from the Centers for Medicare and Medicaid Services (CMS). From July 1, 2023, to December 31, 2024, seven ClinReview pharmacists (CRPs) within five EOM-participating practices in The Network evaluated more than 5,600 patients for medication initiatives. During the same period, The Network had 12 practices in the EOM nationwide, accounting for approximately 50% of all providers participating in the program. A total of 1,271 interventions were identified, with 1,180 accepted. The sum of TCOC reduction amounted to $8,982,235. Six medication initiatives were implemented and the breakdown of each initiative and average TCOC reduction per intervention are shown in the table below and will be presented in a rapid oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: EOM Initiative Number ofinterventions TCOC Reduction Average TCOCReduction perintervention Monoclonal antibody (moAB) dose rounding 443 (35%) $1,537,273 $3,470 Pembrolizumab dose banding 106 (8%) $1,962,105 $18,510 Biosimilar therapeutic interchange (TIC) 356 (28%) $1,510,945 $4,244 Preferred PD-1 agent in metastatic non-small cell lung cancer (NSCLC) 26 (2%) $153,117 $5,889 Decreased use of long-acting growth factor (GF) in metastatic cancer 37 (3%) $109,822 $2,968 Preferred use of zoledronic acid 181 (14%) $2,157,895 $11,992 In addition to the six medication initiatives outlined above, the CRPs contributed an additional $1,201,326 in medication savings associated with drug selection. "With the national cost of cancer care estimated to exceed $245 billion by 2030, this study provides a clear roadmap for oncology practices looking to reduce costs and improve patient outcomes," said lead author Daniel Kendzierski, PharmD, senior clinical pharmacist, The Network. "These findings underscore the critical role of pharmacist-driven medication interventions in driving the success of value-based care models in oncology." Study Methodology Medication initiatives were clinically evaluated and adopted at an individual practice level and included moAB dose rounding, pembrolizumab dose banding, biosimilar TIC to preferred products, use of a preferred PD-1 agent in metastatic NSCLC, decreased upfront usage of long-acting GF in metastatic cancer, and preferred use of zoledronic acid over alternatives. CRPs remotely reviewed oncology treatment orders for cost-savings opportunities, updated eligible treatments per practice protocols, or reviewed with the treating oncologist. Interventions were submitted by the CRPs into a tracking system and marked as an EOM-related intervention. TCOC reduction was calculated using the difference between the CMS allowable for the original treatment ordered and the new order. Other Research at ASCO 2025 Physicians in The Network are affiliated with dozens of studies being presented at ASCO 2025. Their research highlights clinical and operational findings covering key topics such as the impact of AI on care delivery, access to oncology resources for minority patient populations, and patient experiences with novel therapies. "As cancer care costs continue to escalate, community oncology practices need novel therapies and innovative solutions to deliver high-quality, affordable care," said Leslie Busby, MD, Pharmacy & Therapeutics Committee chair and incoming chief medical officer, The Network. "Research presented at this year's ASCO around digital transformation and patient care delivery in community settings highlights the direct impact practices in The Network have on the communities they serve. This research helps inform how we can continue driving value-based care forward and improving cancer care for all oncology patients." The Network is supported by McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. Click here for a full list of SCRI-affiliated studies and presentations and here for Ontada-affiliated abstracts. Expert Panel on Precision Medicine in Community Oncology during ASCO 2025 Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 4, 2025, at 12:10pm ET, titled, "The Future is Now: Digital Transformation Unleashes Precision Medicine in Community Oncology." Click here to register and join the panelists as they share their insights and perspectives on actionable steps and solutions for community oncology practices to seamlessly integrate precision medicine into their care offerings: Jason Hammonds, chief operating officer, Oncology & Specialty, McKesson Andrew McKenzie, PhD, vice president, Personalized Medicine, SCRI and scientific director of Genospace Eric Lander, MD, oncologist, Minnesota Oncology, a practice in The US Oncology Network Terri Conneran, founder of KRAS Kickers ### About The US Oncology Network Every day, The US Oncology Network (The Network) helps more than 2,700 independent providers deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere. About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines. View source version on Contacts Media Contact The US Oncology NetworkClaire Crye, Communications281.825.9927 GCI Health on behalf of The US Oncology NetworkChristine Murphy, Media Relations201.230.9636
Time of India
21-05-2025
- Business
- Time of India
Star Health urges lower costs for sustainability
Representative image MUMBAI: The country's largest standalone health insurer, Star Health and Allied Insurance , called for further reduction in distribution costs, including commissions, to make health insurance more sustainable. The company's CEO, Anand Roy, said that while the current cap on management expenses stands at 35%, it should be reduced gradually by a percentage point every year. "We are among the few companies operating within the expense of management (EOM) limits," Roy said, adding that "bringing this cap down over time is essential to bring down the cost of insurance." He also called for GST waivers on health premiums for senior citizens and vulnerable groups and urged for greater regulation in healthcare delivery, which remains largely unregulated compared to the insurance sector. On medical inflation, Roy said that while the headline figure of 14%, which is always talked about in the industry, may not apply uniformly, it reflects the broad trend in the insured population. "For us, it may be closer to 8-10% depending on the hospital," he said. He attributed rising costs to growing consumer preference for advanced treatments and high-end implants. Roy said moderate and regular hikes in premiums are inevitable but suggested discounts for customers maintaining good health as a way to keep premiums affordable. "Ideally, 2-3% of a family's income should go towards health insurance," he said, recommending higher allocations for those covering parents or in-laws. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Associated Press
17-03-2025
- Business
- Associated Press
Saint-Gobain North America's Essentials of Manufacturing (EOM) Program
Originally published on Saint-Gobain North America LinkedIn For people entering the workforce with a degree in engineering, one of the best ways to start a career is through an early career program such as Saint-Gobain North America's Essentials of Manufacturing (EOM) program. Over the course of 18 months, participants work in a full-time operational role while learning about Saint-Gobain's business, products, and bridging the gap between educational theory and real-life manufacturing practices. Mackenzie Moore, a West Virginia University graduate and EOM Engineer at the CertainTeed Gypsum Plant in Moundsville, WV, graduated from the Essentials of Manufacturing program in December 2024. She continued to learn technical and soft skills through the program while she was still in a learning mindset. The supportive environment of this program allows for engineers to work through challenges as part of the learning process. 'The EOM program has given me the opportunity to grow in ways I didn't think were possible before joining Saint-Gobain. I was able to travel across the US, visiting different plants and learning about various processes, which pushed me outside of my comfort zone and kept me learning.' – Mackenzie Moore When Allie Brayton joined EOM in 2023, she was transitioning from the world of R&D into manufacturing and did not know the doors this opportunity would open for her. 'The various learning and development opportunities provided by the program along with the superb networking helped me flourish in this company right from the get-go, which has helped progress my career far beyond where I thought I would go,' said Allie. 'In such a short period of time, I have moved from a local plant to a national role and now into a global position in under two years.' One of the greatest advantages of the EOM program is the breadth of knowledge and experience it provides, according to Megan Conard, current EOM engineer. Not only does the Essentials of Manufacturing program encourage strong connections within the industry, it can open a variety of different doors. Megan, Mackenzie, and Allie are currently enrolled in the company's Essentials Global Experience, an international career development opportunity in Paris, France. Many people who graduate from Essentials of Manufacturing enter into full-time careers within Saint-Gobain, like Benjamin Thieme, current Plant Manager at our GCP facility near Chicago, IL. When he began his career as an EOM engineer for ADFORS in 2022, he imagined that he would be designing and making parts for a company. At Saint-Gobain, he was exposed to so many different aspects of the manufacturing industry, and his career has thrived. 'From an overall standpoint, the EOM program exposed me to the Saint-Gobain way of doing things,' said Ben. 'I didn't feel like just an ADFORS employee but had more visibility into what all of Saint-Gobain North America was doing. So now at my plant in Chicago, I know what Saint-Gobain wants across all its businesses and how I can drive those initiatives at my plant.' As part of our current and largest EOM cohort to date, Jake Mcbride says working as a sustainability engineer has been an amazing opportunity for him. He's been able to lead projects and contribute meaningful change, which is a different experience than many of his friends from college. There are so many possibilities for career and personal growth with Saint-Gobain North America. And we are currently hiring for the next cohort of Essentials of Manufacturing Engineers in both the United States and Canada. Check out our open .
